Tuesday, July 10, 2018

Investor Ideas #Potcasts; #Cannabis News and Stocks on the Move; CSE: $SNN.C, CSE: $HUGE.C, CSE: $PILL.C, TSXV: $OGI.V, CSE: $HIKU.C, CSE: $MYM.C, OTC: $CBIS, CSE: $CALI.C

Investor Ideas #Potcasts; #Cannabis News and Stocks on the Move; CSE: $SNN.C, CSE: $HUGE.C, CSE: $PILL.C, TSXV: $OGI.V, CSE:  $HIKU.C, CSE: $MYM.C, OTC: $CBIS, CSE: $CALI.C

July 10th #Potcast sponsored by Lexaria Bioscience ( CSE: $LXX.C ) (OTC: $LXRP) a #Cannabis company with a new disruptive drug delivery platform: DehydraTECH 

Pt. Roberts, WA; Delta, BC –July 10, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca  release today’s edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the July 10th podcast:

Today’s podcast overview/transcript:

Good morning and welcome to another Investorideas.com potcast; looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s potcast was sponsored by Kelowna based Lexaria Bioscience Corp trading on the CSE under symbol LXX and on the OTC as LXRP.  Lexaria has developed a new disruptive drug delivery platform: DehydraTECH The Company’s patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally:
1) Masks unwanted tastes – eliminates the need for sugar-filled edibles.
2) Reduces time of onset – effects are felt within 15-20 min vs. 60-120 min.
3) Avoids first-pass liver metabolism
4) Increases bio-absorption by 5-10X
The Company’s DehydraTECH™ technology is patent-protected for multiple APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine and Fat soluble vitamins.
Learn more about Lexaria at www.lexariabioscience.com

Today’s  podcast features news announcements from Sunniva Inc ( CSE:SNN) , FSD Pharma Inc. ( CSE: HUGE and  OTC as FSDDF) , Canntab Therapeutics Limited ( CSE: PILL) , Organigram Holdings Inc. (TSX-VENTURE:OGI) , Hiku Brands Company Ltd ( CSE:HIKU) , MYM Nutraceuticals Inc ( CSE:MYM and  OTC: MYMMF) , Cannabis Science. (OTC: CBIS ) and FinCanna Capital Corp. (CSE: CALI). 

Sunniva Inc., a North American provider of cannabis products and services, announced that it intends to spin out its Canadian assets into a separate Canadian entity and apply to list the shares on the Toronto Stock Exchange (“TSX”) and the NASDAQ Stock Market (“NASDAQ”) in an effort to unlock the underlying value of the Company’s assets on both sides of the border. The Company has retained Canaccord Genuity Corp. to act as a financial advisor in connection with the Spinout Transaction and other strategic initiatives.
The Company expects the Spinoff Transaction will be completed prior to the end of 2018.

FSD Pharma Inc., which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, announced that it has entered into a non-binding letter of intent with Canntab Therapeutics Limited (CSE: PILL), a leader in the rapidly growing cannabis pill market. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act and will provide Canntab with space at its 620,000 square foot facility, which is located just one hour east of Toronto in Cobourg, Ontario.

FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility. Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers.  FSD Pharma and Canntab see tremendous opportunity in offering pharmaceutical quality cannabis based tablets, as many doctors are averse to prescribing smoked cannabis as a solution to patients' health concerns. The Canntab Premises are intended to be used to supply Canadian and International markets such as Australia and Germany, which legally allow cannabis. FSD Pharma will work with Canntab to prepare the necessary items to submit an application from Canntab to Health Canada to obtain the License, which will be attached to the Canntab Premises.

Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of medical marijuana, announced that it has entered into a letter of intent with Hiku Brands Company Ltd. (CSE: HIKU).

As an approved supplier to Manitoba Liquor & Lotteries ("MBLL"), Organigram will supply Hiku with up to 1,000 kg of premium cannabis products per year for the term of the three-year agreement. Products include both dried cannabis and cannabis oils, which will be sold through designated Tokyo Smoke retail locations in Manitoba.
"Organigram and Hiku share a deep commitment to exceptional quality and innovative products," says Greg Engel, CEO, Organigram. "As we move towards a legal, adult recreational use cannabis market, we are proud to be affiliated with companies and brands with a clear and demonstrated focus on their customers and a first-class customer experience."

MYM Nutraceuticals Inc., announced that it has entered into an Investment Agreement to acquire a 49% stake in Colombian cannabis company, Colombia Organica, that currently holds a seed to sale license for low THC cannabis. This license permits Colombia Organica to grow, produce and create cannabis derivatives to be commercialized and / or exported. Further, Colombia Organica is in the licensing process for the cultivation and production of high THC cannabis extracts.

MYM and Colombia Organica have plans to build a production facility near Medellin, Colombia for the cultivation and processing of cannabis and cannabis products. Currently, Colombia Organica is developing and registering seed strains with the Colombian Agricultural Institute.

Cannabis Science, Inc., a U.S. company specializing in the development of cannabinoid-based medicines, announced the immediate launch of a new 40-acre industrial hemp research and development project in Nevada. Cannabis Science, American States University (ASU), FSO NAC / HRM Farms celebrate as the Lincoln County, Nevada industrial hemp property has just been approved by the Nevada Department of Agriculture Industrial Hemp Program. The Group will immediately commence its industrial hemp research operations on the 40-acre Lincoln County, Nevada property.

The Group believes it can bring in one and quite possibly two harvests this year. The primary purpose of the research initiative is to provide hands-on University professional training in agricultural industrial hemp research and development focused on creating pharmaceutical drugs targeting critical ailments while furthering the Group’s other industrial targets such as Alternate Biofuels, Construction, Clothing and Automobile Materials, and other industries. The University programs aim to provide affordable quality education to its students so as to achieve their career goals and excel in their chosen professions. 

FinCanna Capital Corp. a royalty company for the U.S. licensed medical cannabis industry, has executed an Expanded Royalty Agreement with Refined Resin Technologies Inc. formerly known as Gram Co Holdings LLC, of Oakland, California. Refined Resin is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain.
FinCanna will fund US$3 million in tranches to complete the original Royalty Agreement transaction that was previously announced under a binding term sheet in February 2018.  In return, FinCanna will receive a tiered corporate royalty, ranging from 14% to 5.0% of Refined

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

This podcast is sponsored by Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP)

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com

Subscribe to the new cannabis podcast series:

To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  
Investorideas.com cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site  Global Cannabis Investing at www.Globalcannabisinvesting.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp

Follow us on Social Media

Contact Investorideas.com


Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory

No comments:

Post a Comment